IP Library › Granted Patent US 9,145,460
Granted Patent B2
US 9,145,460 · App. 13/913,587 · Granted Sep 29, 2015

Compositions and methods for diagnosing and treating an inflammation

Inventors: Nathan Karin (Haifa, IL); Rachel Anunu (Haifa, IL); Gizi Wildbaum (Kiryat Yam, IL); Yaniv Zohar (Kiryat-Haim, IL); Nir Netzer (Mazkeret Batia, IL)
Assignee: RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES
C07K16/28A61K39/3955C07K16/2896G01N33/6893A61K2039/505C07K2317/21C07K2317/565C07K2317/567C07K2317/76G01N2333/70596G01N2800/065G01N2800/202
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,145,460
App. No.
13/913,587
Granted
Sep 29, 2015
Kind
B2
Abstract

An isolated polypeptide is provided. The polypeptide comprising an antigen recognition domain capable of specifically binding a human scavenger receptor, wherein the antigen recognition domain comprises at least three CDR amino acid sequences selected from the group consisting of SEQ ID NO: 11, 15, 19, 23, 27 and 31. Also provided are compositions which comprise the peptide and uses of same.

Claims (6)

1. A method of treating an inflammatory disease in a subject in need thereof, the method comprising administering to said subject a therapeutically effective amount of an isolated polypeptide comprising an antigen recognition domain capable of specifically binding a human scavenger receptor, wherein said antigen recognition domain comprises CDR amino acid sequences as set forth in SEQ ID NO: NO: 11, 15, 19, 23, 27 and 31, thereby treating the inflammatory disease in the subject.

2. The method of claim 1 , wherein said inflammatory disease is an autoimmune inflammatory disease.

3. The method of claim 2 , wherein said autoimmune inflammatory disease is selected from the group consisting of Systemic Lupus Erythematosus (SLE), Amyotrophic Lateral Sclerosis (ALS) and Rheumatoid Arthritis (RA).

4. The method of claim 2 , wherein said autoimmune inflammatory disease is Systemic Lupus Erythematosus (SLE).

5. The method of claim 2 , wherein said autoimmune inflammatory disease is Amyotrophic Lateral Sclerosis (ALS).

6. The method of claim 2 , wherein said autoimmune inflammatory disease is Rheumatoid Arthritis (RA).

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 28, 2018
From: RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES
To: TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED
Reel/Frame 046493/0824 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 15, 2013
From: KARIN, NATHAN; ANUNU, RACHEL; WILDBAUM, GIZI; ZOHAR, YANIV; NETZER, NIR
To: RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES
Reel/Frame 031013/0689 →
Continuity (6)
Division 11991711
Continuation In Part 11222745 · Sep 12, 2005
Continuation In Part PCTIL2004000241 · Mar 14, 2004
Provisional Application 60453512 · Mar 12, 2003
Provisional Application 60453514 · Mar 12, 2003
Related Publication 20140161823A1 · Jun 12, 2014